Dispatches from PCT

Not all good news: CROs must prepare for Private Equity exit, experts say

By Dan Stanton contact

- Last updated on GMT

Private Equity has to exit CRO industry at some point, experts say
Private Equity has to exit CRO industry at some point, experts say
Private equity will be looking to exit the CRO industry and could pose a threat to recent strong growth, according to financial experts at PCT

As opposed to pharma companies hit by high costs, patent expiration and trailing pipelines, contract research organisations (CROs) are reporting high growth rates: “about as high as they’ve ever been with Wall Street thinking they will continue to do well,” ​Director of Fairmount Partners Michael Martorelli told a crowded room at PCT Vienna last week.

However, he warned, “trees do not grow to the sky”​ and whilst the overall industry may be in a boom there are still a number of potential landmines that could overturn both individual companies and the wider market.

One of these is the growing interest from private equity (PE) firms in the sector and the future opportunities for them to exit as - he pointed out - a fruitful exit strategy was why they had invested in the first place.

In the last three years twelve CROs had been acquired by (all US-based) PE firms including inVentiv​, INC Research​, PRA​, MedPace​, Theorem​ and PPD​, he said.

Uncertain Exit

Paul Richter, Head of Life Sciences at Jina Ventures also spoke about PE’s involvement in CROs, saying whilst there is a certain amount of transparency amongst the public CROs - Quintiles, Icon and Covance for example reporting book-to-bill ratios of 1.44, 1.4 and 1.21 respectively - when it comes to the private CROS and how they are doing: “We have no idea!”

He concluded: “PE firms have to exit its CRO investments within the next five years”​ but how exactly is unclear.

Discipline

However, Martorelli acknowledged private equity firms didn't all have the same motive. “Saying one PE is the same as another PE is like saying one CRO is the same as another CRO. All PEs are different and differently motivated.”

“Done correctly, a PE should use appropriate amounts of private finance,”​ he continued and “some CROs only find out they needed financial discipline once a PE came in.”

Other Pitfalls

Other fears Martorelli highlighted that may make the CRO industry stumble included clinical research issues in India​, nervous stock investors and unexpected quality and financial problems.

One other is Big Pharma’s limitations on R&D spending. For example Merck & Co.’s recent announcement that it was to cut R&D by $2.5bn has since led to stakeholder uncertainty and questions at CROs Charles River Laboratories​ and WuXi​.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers